title: Review of pharmacotherapy options for the management of obesity.
abstract: OBJECTIVE
  To highlight the prevalence and impact of obesity in the United States and provide nurse practitioners (NPs) with an overview of pharmacotherapy options for treatment of overweight and obese individuals.
  
  
  METHODS
  A comprehensive review of the literature was conducted using multiple databases, including PubMed, MEDLINE, and Ovid. Keywords used to obtain relevant articles included obesity and drug, or orlistat, topiramate/phentermine, lorcaserin, bupropion/naltrexone, and liraglutide.
  
  
  CONCLUSIONS
  Obesity is a prevalent disease with more than two thirds of Americans being considered overweight and one third being obese. Obesity places patients at an increased risk for many comorbidities that impact patient health as well as public health. There are currently five approved medications for the chronic management of obesity, two of which were approved in 2014. These pharmacological therapies are options to aid weight loss in patients that are obese or those who are overweight with additional risk factors.
  
  
  CONCLUSIONS
  NPs can assist patients struggling with their weight. With new pharmacotherapy options, there is an opportunity to add to diet and exercise in order to achieve increased weight loss. A decrease in obesity would potentially alleviate the burden on the healthcare system, both socially and economically, and improve patient quality of life.
authors.affiliation: St. Louis College of Pharmacy, St. Louis, Missouri.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Bragg
authors.affiliation: St. Louis College of Pharmacy, St. Louis, Missouri.
authors.forename: Erica
authors.initials: E
authors.lastname: Crannage
mesh_terms: D001552:Benzazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016642:Bupropion / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D019468:Disease Management; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000069450:Liraglutide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009271:Naltrexone / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D010645:Phentermine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077236:Topiramate; D014481:United States
chemical_list: D001552:Benzazepines; D007783:Lactones; D016642:Bupropion; D000077236:Topiramate; D005632:Fructose; D009271:Naltrexone; C506658:lorcaserin; D000069450:Liraglutide; D000077403:Orlistat; D010645:Phentermine
keywords: Obesity; pharmacotherapy; weight management; weight regulation